# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
GT Biopharma (NASDAQ:GTBP) reported quarterly losses of $(2.17) per share. This is a 45.64 percent decrease over losses of $(1....
GTB-3650 Phase 1 trial initiation expected in H2 2024; initial clinical data expected in H1 2025GTB-5550 TriKE® IND submission ...
GT Biopharma entered into a definitive securities purchase agreement for the purchase and sale of 740,000 shares of its common ...